An OTC monograph defines the actives, doses, indications, warnings and labeling allowed for a class of over-the-counter drugs — sunscreens, antiseptics, antiperspirants, anti-acne, cough/cold, oral analgesics, antifungals and more. Products that conform to a monograph and meet 21 CFR Part 330 can be marketed without an individual NDA.

Since the 2020 OTC Monograph Reform (CARES Act), FDA can revise monographs via Administrative Order on a faster timeline than full rulemaking. Manufacturers need to track open Administrative Order proceedings against their products so a regulatory change (e.g., on sunscreen actives or hand-sanitizer specifications) drives a planned label and formula revision rather than a fire drill. Monograph drugs remain subject to 21 CFR 211 cGMP in full and pay OMUFA fees annually.

Regulatory anchors

21 CFR 330
21 CFR 201.66

Industries that live with this

Pharmaceutical Consumer Products

How V5 handles it

Document control with hard kiosk-level training enforcement.

Versioned SOPs are only useful if operators are actually trained on the current version. V5 enforces it at the kiosk.

MES — operator execution that writes its own batch record.

V5’s MES isn’t a dashboard — it’s the kiosk in the operator’s hands. Every action is signed, in sequence, with the device evidence already attached.

eBMR / eDHR — the batch record writes itself.

When the master is locked and the operator works on the kiosk, the batch record is no longer something to assemble — it’s something to render.

Related terms

OMUFA